Abstract
Historically, the medical oncologist has been involved in the care of prostate cancer patients at the end of their lives; however, with newer chemotherapy interventions, clinical trials, more options, and increased involvement of patients in their medical care, the role of the medical oncologist should be revisited. A survey of the practice of British urologists clearly demonstrates the problem. “In clinical practice, 82% of urologists have close links with oncology, available through joint clinics or on-site referral. However, <5% refer patients to an oncologist before the development of hormone refractory disease. At relapse, only 53% of urologists referred their patients to oncologists or palliative-care clinicians. A wide variety of hormonal treatments were offered at relapse; only 24% of urologists treated their patients by antiandrogen withdrawal or introduction, which is currently, the most effective second-line treatment for recurrent prostate cancer” (1). With involvement from the day of diagnosis, the medical oncologist can assist in the coordination of treatments and the appropriate application of interventions. The assumption of the authors of this chapter is that it is never too early to refer a patient to a medical oncologist.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Savage P, Bates C, Abel P, et al. British urological surgery practice 1. Prostate cancer. Br J Urol 1997; 79: 749–755.
Moore MJ, O’Sullivan B, Tannock IF. Are treatment strategies of urologic oncologists influenced by the opinions of their colleagues? Br J Cancer 1990; 62: 988–991.
Moore MJ, O’Sullivan B, Tannock IF. How expert physicians would wish to be treated if they had genitourinary cancer. J Clin Oncol 1988; 6: 1736–1745.
Crawford ED, Bennett CL, Stone NN, et al. Comparison of perspectives on prostate cancer: analysis of survey data. Urology 1997; 50: 366–372.
O’Rourke M. Narrowing the options: the process of deciding on prostate cancer treatment. Cancer Invest 1999; 17: 349–359.
Moul JW. Therapy of early progression of prostate cancer. Clin Oncol Updates 1998; 1: 1.
Small EJ. Prostate cancer. Curr Opin Oncol 1997; 9: 227.
Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001; 58: 843–848.
D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy or interstitial radiation for clinically localized prostate cancer. JAMA 1998; 280: 969–974.
Graefen M, Karakiewicz PI, Cagiannos I, et al. International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2002; 20: 3206–3212.
Soloway MS, Pareek K, Sharifi R, et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5 year results. J Urol 2002; 167: 112–116.
Zietman AL, Vogelzang PT, Scardino DS, et al. Locally advanced or recurrent prostate cancer. In: Comprehensive Textbook of Genitourinary Oncology. Wilkins & Wilkins, Baltimore, 1996, pp. 782–790.
Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 2002; 360: 103–106.
Dawson NA, Figg WD, Cooper MR, et al. Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer. J Clin Oncol 1997; 15: 1470–1477.
Pettaway CA, Pisters LL, Troncoso P, et al. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J Clin Oncol 2000; 18: 1050–1057.
Zelefsky MJ, Kelly WK, Scher HI, et al. Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three dimensional conformal radiotherapy for patients with locally advanced prostate cancer. J Clin Oncol 2000; 18: 1936–1941.
Wang J, Halford S, Rigg A, et al. Adjuvant mitaxantrone chemotherapy in advanced prostate cancer. Br J Urol Int 2000; 86: 675–680.
Murphy GP, Beckley S, Brady MF, et al. Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 1983; 51: 1264–1272.
Osborne CK, Blumenstein B, Crawford ED, et al. Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study. J Clin Oncol 1990; 8: 1675–1682.
Huben RP, Murphy GP. A comparison of diethylstilbestrol or orchiectomy with buserelin and with methotrexate plus diethylstilbestrol or orchiectomy in newly diagnosed patients with clinical stage D2 cancer of the prostate. Cancer 1986; 62: 1881–1887.
Seifter EJ, Bunn PA, Cohen MH, et al. A trial of combination chemotherapy followed by hormonal for previously untreated metastatic carcinoma of the prostate. J Clin Oncol 1995; 4: 1365–1373.
Vandenbroucke F, Van Poppel H, Derluyn J, et al. Interim results on a randomized trial of mitomycin C in combination with orchiectomy for newly diagnosed metastatic prostate cancer. Am J Clin Oncol 1995; 18: 263–266.
Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 28: 1591–1597.
Hussain A, Dawson N, Amin P, Naslund M, Engstrom C, Chen T, Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results. Semin Oncol 2001; 28 (suppl 15): 22–31.
Robson M, Dawson N. How is androgen dependent metastatic prostate cancer best treated? Hematol Oncol Clin North Am 1996; 10: 727–747.
Jemal A, Murray T, Samuels A. Cancer statistics, 2003. CA 2003; 53: 5–26.
Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 6: 1756–1764.
Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999; 17: 2506–2513.
Osoba D, Tannock IF, Ernst DS, et al. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 1999; 17: 1654.
Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458–1663.
Lipton A, Small E, Saad F, et al. The new bisphosphonate, Zometa® (zoledronic acid) decreases skeletal complications in both lytic and blastic lesions: a comparison to pamidronate. Cancer Invest 2002; 20 (suppl 1): 44–46.
Gulley J, Figg W, Dahut W, et al. Treatment options for androgen independent prostate cancer. Clin Adv Hematol Oncol 2003; 1: 40.
Hussain A, Dawson NA. Management of advanced/metastatic prostatic cancer—2000 update. Oncology 2000; 14: 1677–1687.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer Science+Business Media New York
About this chapter
Cite this chapter
Smoot, J., Dawson, N.A. (2004). When to Refer a Patient With Prostate Cancer to a Medical Oncologist. In: Klein, E.A. (eds) Management of Prostate Cancer. Current Clinical Urology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-776-5_30
Download citation
DOI: https://doi.org/10.1007/978-1-59259-776-5_30
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4757-5711-8
Online ISBN: 978-1-59259-776-5
eBook Packages: Springer Book Archive